| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
143,000,000 |
| Market
Cap: |
1.88(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.47 - $31.58 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1228 |
| Guru Rank Value : -1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
501,962 |
501,962 |
755,740 |
1,033,448 |
| Total Sell Value |
$7,520,798 |
$7,520,798 |
$14,150,751 |
$19,879,078 |
| Total People Sold |
3 |
3 |
6 |
7 |
| Total Sell Transactions |
4 |
4 |
20 |
55 |
| End Date |
2025-06-15 |
2025-03-14 |
2024-09-13 |
2023-09-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Watts Ryan J. |
President and CEO |
• • – |
2025-09-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
50,000 |
2,152,604 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2025-08-13 |
4 |
AS |
$14.64 |
$11,800 |
D/D |
(806) |
216,585 |
|
-4% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-08-12 |
4 |
S |
$13.58 |
$39,884 |
D/D |
(2,937) |
242,346 |
|
-7% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2025-08-12 |
4 |
AS |
$13.58 |
$39,884 |
D/D |
(2,937) |
217,391 |
|
7% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2025-08-05 |
4 |
OE |
$0.68 |
$30,365 |
D/D |
44,655 |
220,328 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2025-07-09 |
4 |
AS |
$15.00 |
$7,429,230 |
D/D |
(495,282) |
253,071 |
|
-5% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2025-07-09 |
4 |
OE |
$0.68 |
$520,792 |
D/D |
495,282 |
748,353 |
|
- |
|
| Baker Julian |
|
– • – |
2025-06-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,731,695 |
|
2% |
|
| Schenkein David P |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
15,257 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
26,075 |
|
- |
|
| Klein Peter S |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
27,533 |
|
- |
|
| Flatley Jay T |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
16,220 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
1,886,576 |
|
- |
|
| Baker Julian |
|
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
I/I |
21,130 |
3,415,958 |
|
- |
|
| Thornberry Nancy |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
24,717 |
|
- |
|
| Krognes Steve E. |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
31,794 |
|
- |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-07 |
4 |
S |
$20.81 |
$60,495 |
D/D |
(2,907) |
244,308 |
|
34% |
|
| Krognes Steve E. |
Director |
– • – |
2025-01-07 |
4 |
S |
$20.81 |
$69,485 |
D/D |
(3,339) |
25,757 |
|
34% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2025-01-07 |
4 |
S |
$20.81 |
$60,495 |
D/D |
(2,907) |
175,673 |
|
34% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2025-01-07 |
4 |
S |
$20.81 |
$159,197 |
D/D |
(7,650) |
253,071 |
|
34% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-06 |
4 |
S |
$20.22 |
$247,796 |
D/D |
(12,255) |
247,215 |
|
30% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2025-01-06 |
4 |
S |
$20.22 |
$247,796 |
D/D |
(12,255) |
178,580 |
|
30% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2025-01-06 |
4 |
S |
$20.22 |
$591,759 |
D/D |
(29,266) |
260,721 |
|
30% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
54,180 |
289,987 |
|
- |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
54,180 |
259,470 |
|
- |
|
480 Records found
|
|
Page 1 of 20 |
|
|
1.03 (7.26%) 
